Videos

César de la Fuente, PhD, provides insights on the promising work of his lab as they accelerate the speed of finding new antimicrobial molecules.

At ASM Microbe 2025, Pelumi Oladipo discusses E marmotae’s reduced motility, misidentification as E coli, and the diagnostic tools closing the gap.

Rafik Samuel, MD, chief of the Section of Infectious Disease at Temple University Hospital and professor of medicine at Lewis Katz School of Medicine at Temple University, talks about its history and the uniqueness of its fellowship program.

Presented at ASM Microbe, Pelumi Oladipo's study identifies the first North American human case of E marmotae infection and introduces methods to improve species-level diagnosis.

Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.

Jason Haukoos, MD, on how the DETECT Hep C trial leverages 24/7 emergency care to reach vulnerable patients.

Margie Lee, DVM, MS, PhD, wants young researchers and providers to know that despite the current environment, this is not the first time science has had to deal with a challenges to research and funding.

Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.

In the second installment of our conversation with Jeremy Faust, MD, he addresses the uncertainty surrounding guidance and where to turn for information.

Jeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.

Jason Haukoos, MD, MSc, FACEP, shares the decade-long journey behind the DETECT Hep C trial and why emergency departments are key to implementing Centers for Disease Control and Prevention screening guidelines.

In our latest podcast, first author Elizabeth Marlowe, PhD, D(ABMM), offers insights on her study looking at this ongoing issue, including the need for increased testing and getting patients into the continuum of care in a more efficient manner.

At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.

At IAS 2025, the VOLITION and OPERA study data show patient preference and real-world use of injectable CAB + RPV LA, informing the treatment strategy of ViiV CMO Jean van Wyk.

Carl Schmid on the US Supreme Court ruling, proposed Centers for Disease Control and Prevention cuts, stigma, and why equitable PrEP access, including new long-acting options, depends on more than insurance.

HIV+Hepatitis Policy Institute director discusses PrEP access, insurer compliance, and challenges ahead following the landmark decision.

In Part 2, Anna Seekatz, PhD and PhD candidate Sophie Millard highlight the need for precision microbial therapies tailored to host-specific gut environments.

Clemson University researchers Anna Seekatz, PhD, and PhD candidate Sophie Millard uncover how functional mismatches between donor microbes and recipient gut environments could limit the success of microbiome-based therapies.

Ep 1, Part 4 of 4, Robert C Bransfield, MD, continues to share how vector-borne infections may trigger psychiatric symptoms not through direct brain infection, but by disrupting immune signaling and gene expression.

Johns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuing education opportunity.

John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.

Paul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).

Rodney Rohde, PhD, SM(ASCP), SVCM, MBCM, FACSc, discusses the ongoing concerns about the federal government’s hold on funding for research and the potential chilling effect that it may have on laboratory professionals and deciding on careers, especially in areas such as public health. He also talks about locating and engaging in potential alternative resources for research funding.

In our latest podcast, Tim Gauthier, PharmD, BCPS, BCIDP, discusses all things pathogens and antibiotics. He also details the opportunities presented for antimicrobial stewardship when it combines diagnostics and treatment duration.

In a wide-ranging interview, Susan Weiss, PhD, talks about winning the ASM Lifetime Achievement award, her work on coronaviruses, and her concerns around federal government funding and how it may shake up and limit basic science research.

At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.

Ep 1, Part 3 of 4 with Robert Bransfield, MD, explores treatment-resistant mental health issues linked to infection history and diverse progression patterns.